DECEMBER 26, 2017
As published in the San Antonio Business Journal
By W. Scott Bailey
It’s been a landmark year for San Antonio’s biotech industry. Multiple companies have hit major milestones en route to greater international expansion and new product development.
Below is a synopsis of some stories I’ve written this year in covering an industry that’s becoming increasingly important to the Alamo City and its connection to a global economy.
San Antonio-based bioAffinity Technologies Inc. hit the jackpot this summer. In July, I reported that the company had closed on its Series A funding round, raising more than $4 million — $1 million more than it had sought.
BioAffinity President and CEO Maria Zannes said the Series A investments would enable the company, which is moving closer to commercializing its CyPath Lung cancer detection system, to pursue development of additional cancer tests and novel therapeutics that can more effectively treat the disease.
“The Series A funding advances both our cancer diagnostic platform and the therapeutic research and development,” she said.